Akari Therapeutics (AKTX) EBITDA (2014 - 2026)
Akari Therapeutics recorded quarterly EBITDA of -$14.4 million in Q1 2026, down 192.56% quarter-over-quarter from -$4.9 million in Q4 2025, and down 286.12% year-over-year from $7.8 million in Q1 2025.
Akari Therapeutics' EBITDA history runs 13 years deep, the most recent figure standing at -$14.4 million for Q1 2026.
- In Q1 2026, EBITDA fell 286.12% year-over-year to -$14.4 million; the TTM figure through Mar 2026 stood at -$28.0 million (down 56.3% YoY), while the FY2025 annual figure was -$17.3 million, up 11.02% from the prior year.
- EBITDA came in at -$14.4 million for Q1 2026 at Akari Therapeutics, down from -$4.9 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $5.7 million in Q2 2022 to a low of -$14.4 million in Q1 2026.
- A 5-year average of -$3.4 million and a median of -$3.7 million in 2025 frame the typical range for EBITDA.
- Across the five-year window, EBITDA jumped 194.15% in 2022 and sank 627.12% in 2024, its largest moves.
- Akari Therapeutics' EBITDA stood at $5.7 million in 2022, then plunged by 175.92% to -$4.3 million in 2023, then increased by 17.59% to -$3.6 million in 2024, then plunged by 37.72% to -$4.9 million in 2025, then slumped by 192.56% to -$14.4 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$14.4 million, -$4.9 million, and -$6.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -445.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.44 Mn |
| Dec 31, 2025 | -4.94 Mn |
| Sep 30, 2025 | -6.44 Mn |
| Jun 30, 2025 | -2.23 Mn |
| Mar 31, 2025 | -3.74 Mn |
| Dec 31, 2024 | -3.58 Mn |
| Sep 30, 2024 | -3.07 Mn |
| Jun 30, 2024 | -7.55 Mn |
| Mar 31, 2024 | -5.29 Mn |
| Dec 31, 2023 | -4.35 Mn |
| Sep 30, 2023 | -2.87 Mn |
| Jun 30, 2023 | -4.06 Mn |
| Mar 31, 2023 | 1.00 Mn |
| Jun 30, 2022 | 5.73 Mn |
| Mar 31, 2022 | 5.21 Mn |
| Dec 31, 2021 | -28.75 Mn |
| Sep 30, 2021 | -1.48 Mn |
| Jun 30, 2021 | 4.42 Mn |
| Mar 31, 2021 | -5.53 Mn |
| Dec 31, 2020 | -6.84 Mn |
| Sep 30, 2020 | 909,778.00 |
| Jun 30, 2020 | 7.49 Mn |
| Mar 31, 2020 | -3.97 Mn |
| Dec 31, 2019 | -7.83 Mn |
| Sep 30, 2019 | -2.88 Mn |
| Jun 30, 2019 | -6.11 Mn |
| Mar 31, 2019 | -79,343.00 |
| Dec 31, 2018 | -3.51 Mn |
| Sep 30, 2018 | 715,846.00 |
| Jun 30, 2018 | -8.02 Mn |
| Mar 31, 2018 | -4.28 Mn |
| Dec 31, 2017 | -12.07 Mn |
| Sep 30, 2017 | 10.29 Mn |
| Jun 30, 2017 | -368,593.00 |
| Mar 31, 2017 | -12.63 Mn |
| Dec 31, 2016 | 8.23 Mn |
| Sep 30, 2016 | 567,456.00 |
| Jun 30, 2016 | 6.61 Mn |
| Mar 31, 2016 | 3.18 Mn |
| Dec 31, 2015 | 6.43 Mn |
| Sep 30, 2015 | -48.78 Mn |
| Jun 30, 2015 | 1.32 Mn |
| Mar 31, 2015 | -1.67 Mn |
| Dec 31, 2014 | -999,994.00 |
| Sep 30, 2014 | -243,520.00 |
| Jun 30, 2014 | -2.33 Mn |
| Mar 31, 2014 | -1.88 Mn |